Recognizing Atopic Dermatitis in Patients with Skin of Color: What Clinicians Often Miss
Atopic dermatitis (AD) can be deceptively tricky in patients with darker skin tones, often leading to delayed diagnosis and treatment. Classic signs like redness and inflammation may be far less noticeable—or even look completely different—compared to lighter skin. This subtlety increases the risk of pigment changes, scarring, and prolonged discomfort. But here's where it gets controversial: many medical training materials and photo atlases still underrepresent patients of color, leaving clinicians underprepared for these nuances.
Vinay Mehta, MD, a board-certified allergist and immunologist with Allergy & Asthma Associates of Southern California, shares practical strategies for improving recognition, diagnosis, and care for patients with skin of color.
Why traditional training can fall short
Mehta emphasizes that most clinicians rely heavily on visual cues seen in textbooks and atlases. "In medical school, residency, and fellowship, we get used to seeing certain images," he explains. "Unfortunately, these rarely include enough examples of patients with darker skin." One striking clinical point he highlights is that erythema—typically a hallmark of inflammation—can be difficult to detect in darker skin. Instead, clinicians should look for dyspigmentation, including both hyperpigmentation and hypopigmentation, which often serves as a more reliable clue for AD in these patients.
Practical tips to improve diagnosis
Mehta recommends a few simple yet effective strategies. For instance, adjusting lighting by turning off overhead lights and using a flashlight can make subtle redness more visible. Additionally, incorporating photo atlases that feature a diverse range of skin tones can dramatically improve diagnostic confidence. Social media platforms can also play a surprising role by providing real-world patient stories that increase awareness and understanding of how AD presents across different skin colors.
Building trust and improving adherence
Treatment of chronic conditions like AD requires strong communication and trust between the clinician and patient. Mehta stresses listening carefully to patients' stories and engaging in shared decision-making. "Understanding their perspective and what's important to them is crucial," he notes. This approach is especially important for long-term therapies, where adherence can be significantly affected by the patient's comfort and trust in their healthcare provider.
Overcoming additional barriers
Barriers extend beyond recognition and diagnosis. Minority populations often face disparities in access to care, insurance coverage, and specialist availability. Language and cultural differences can further complicate treatment. "Spending the time to develop trust isn't just a courtesy—it directly impacts adherence," Mehta emphasizes. Chronic diseases like AD demand ongoing therapy, and without effective communication, patients may struggle to follow through with treatment plans.
Managing pigmentation changes and scarring
Pigmentary alterations and scarring are particularly concerning for patients with darker skin. Mehta suggests early intervention with systemic therapies, such as biologics or oral JAK inhibitors, rather than relying solely on topical treatments. "Starting systemic therapy sooner can help prevent some of these long-term pigmentary and scarring issues," he explains. This proactive approach highlights the importance of timely and individualized care.
The bigger picture
The discussion around AD in patients with skin of color is not just a clinical issue—it’s a call to reexamine medical education, expand research, and address healthcare inequities. Are current guidelines truly sufficient for all populations, or are we overlooking key differences that could improve outcomes? Clinicians, patients, and educators alike must consider these questions as we strive for more inclusive and effective dermatologic care.
Newsletter: Join thousands of healthcare professionals keeping up-to-date with new therapies, trial data, and expert insights by subscribing to HCPLive today.
